Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00047177 · ClinicalTrials.gov registry record · Phase 2

Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Pediatric Brain Tumor Consortium.

Completed
Registry status
Phase 2
Development phase
43
Enrollment target
10
Study locations

NCT00047177 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 43 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (77% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00047177, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Pediatric Brain Tumor Consortium.

COMPLETED
Registry status
Phase 2
Development phase
43 participants
Enrollment target
10
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating children who have recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal or atypical teratoid rhabdoid tumor.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • DRUG Oxaliplatin

Study Locations (10)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Children's Hospital of Pittsburgh - Pittsburgh

California

  • UCSF Comprehensive Cancer Center - San Francisco

District of Columbia

  • Children's National Medical Center - Washington D.C.

Illinois

  • Children's Memorial Hospital - Chicago - Chicago

Massachusetts

  • Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston

North Carolina

  • Duke Comprehensive Cancer Center - Durham

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Texas

  • Texas Children's Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2002-10
Est. Completion 2007-07
Phase Phase 2

Sponsor

Pediatric Brain Tumor Consortium

27 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00047177

The ClinicalTrials.gov registry entry for NCT00047177 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (77% lower). The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which Oxaliplatin is the first listed.

NCT00047177 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, California, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00047177 about?

NCT00047177 is a clinical study titled "Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating children who have recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal o...

What is the current status of trial NCT00047177?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2002-10. Estimated completion is 2007-07.

What conditions does trial NCT00047177 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00047177?

The interventions under investigation include: Oxaliplatin (DRUG).

Who is sponsoring clinical trial NCT00047177?

This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00047177 being conducted?

This trial has 10 study locations across California, District of Columbia, Illinois, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain and Central Nervous System Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.